Aged ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Bleomycin ; therapeutic use ; Dacarbazine ; therapeutic use ; Doxorubicin ; therapeutic use ; Hodgkin Disease ; drug therapy ; pathology ; Humans ; Leukemia, Hairy Cell ; drug therapy ; pathology ; surgery ; Male ; Mitoxantrone ; administration & dosage ; Neoplasms, Multiple Primary ; drug therapy ; pathology ; surgery ; Rituximab ; Splenectomy ; Vidarabine ; administration & dosage ; analogs & derivatives ; Vinblastine ; therapeutic use

Diagnosis, Differential ; Gene Rearrangement ; Hodgkin Disease ; genetics ; metabolism ; pathology ; Humans ; Lymphoma, B-Cell ; genetics ; metabolism ; pathology ; Lymphoma, Large B-Cell, Diffuse ; genetics ; metabolism ; pathology ; Mediastinal Neoplasms ; genetics ; metabolism ; pathology ; Proto-Oncogene Proteins c-bcl-2 ; genetics ; metabolism

Diagnosis, Differential ; Humans ; Lymphoproliferative Disorders ; diagnosis ; Stomach ; Stomach Neoplasms ; diagnosis

Actins ; metabolism ; Breast ; cytology ; metabolism ; Breast Neoplasms ; metabolism ; pathology ; Cell Differentiation ; Female ; Humans ; Keratins ; metabolism ; Neoplastic Stem Cells ; metabolism ; pathology ; Signal Transduction ; Stem Cells ; cytology ; metabolism

Humans ; Male ; Splenectomy ; Stem Cell Transplantation ; adverse effects ; Thrombocytopenia ; etiology ; surgery ; Thrombotic Microangiopathies ; complications ; surgery ; Young Adult

Aged ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antigens, CD20 ; metabolism ; Antineoplastic Agents ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; CD5 Antigens ; metabolism ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell ; drug therapy ; metabolism ; pathology ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; metabolism ; pathology ; Male ; Prednisone ; therapeutic use ; Receptors, IgE ; metabolism ; Rituximab ; Vincristine ; therapeutic use

Aged, 80 and over ; Antigens, CD20 ; metabolism ; CD79 Antigens ; metabolism ; Diagnosis, Differential ; Humans ; Interferon Regulatory Factors ; metabolism ; Ki-67 Antigen ; metabolism ; Leukosialin ; metabolism ; Lymphoma, Large B-Cell, Diffuse ; metabolism ; pathology ; surgery ; Male ; Neoplasms, Muscle Tissue ; metabolism ; pathology ; Prostatic Neoplasms ; metabolism ; pathology ; surgery ; Prostatitis ; metabolism ; pathology ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Receptor Protein-Tyrosine Kinases ; metabolism

Aged ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antigens, CD20 ; metabolism ; Antineoplastic Agents ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Bleomycin ; therapeutic use ; CD79 Antigens ; metabolism ; Cyclophosphamide ; therapeutic use ; Dacarbazine ; therapeutic use ; Doxorubicin ; therapeutic use ; Female ; Hodgkin Disease ; drug therapy ; metabolism ; pathology ; surgery ; Humans ; Lymphoma, Large B-Cell, Diffuse ; metabolism ; pathology ; surgery ; therapy ; Neoplasms, Second Primary ; metabolism ; pathology ; surgery ; therapy ; Prednisone ; therapeutic use ; Rituximab ; Vinblastine ; therapeutic use ; Vincristine ; therapeutic use

Objective To explore the clinical significance of monocyte chemoattractant protein-1(MCP-1)in children with Henoch-Schonlein purpura nephritis(HSPN).At the same time compare the association between serum and urine MCP-1,to investigate the impact of the both on them in children with HSPN.Methods Serum and urine MCP-1 were measured by enzyme linked immunosorbent assay in 50 children with Henoch-Schonlein purpura(HSP)(25 cases of them patients with renal injures),and 25 healthy children,the changes of serum and urine MCP-1 were compared;at the same time serum urea nitrogen,creatinine,urinary albumin,urine N-acetyl-D-glucosaminidase(NAG),urine ?2-MG,24 hours urinary levels of protein were investigated in children with HSPN by analyzing the correlation between these indicators and serum and urine MCP-1;urine MCP-1 in HSPN group were measured in recovery period,and were compared with urine MCP-1 in HSP group and HSPN group in acute period.Results 1.The expressions of urine MCP-1 was significantly higher in HSPN group than those in HSP group and healthy controls(P0.05).2.Urine MCP-1 levels were associated with proteinuria in children with HSPN,but serum MCP-1 levels had nothing to do with HSPN.3.There was a close correlation between urine MCP-1 expression and urinary albumin,urine NAG,urine ?2-MG and 24 hours urinary levels of protein,but the expression of urine MCP-1 levels were not correlated with the serum urea nitrogen and creatinine.4.There was statistical significance in urine MCP-1 in acute and recovery periods with HSPN group(P

Objective To explore the roles of reactive oxygen species(ROS) and TGF-?1 in aldosterone-induced PAI-1 production.Methods Quiescent rat mesangial cells (MCs) were treated by aldosterone.The level of ROS in MCs induced by aldosterone was measured by confecal laser scanning microscopy and the TGF-?1 activity in the supematant of culture was measured by mink lung epithelial cell (Mvllu) proliferation inhibition MTT assay.Then,before the addition of aldosterone,MCs were pretreated with NAC or TGF-?1 neutralizing antibody to decrease cellular ROS or inhibit activity of TGF-?1 induced by aldosterone respectively.PAI-1 mRNA was examined by semi-quantification RT-PCR and PAI-1 protein by Western blotting.Results The intracellular ROS induced by aldosterone increased by 5-fold compared to that of control group,and the activity of TGF-?1 stimulated by aldosterone increased markedly.TGF-?1 neutralizing antibody and NAC effectively decreased aldosterone-induced PAI-1 mRNA expression by 30% and 32%,and PAI-1 protein expression by 21% and 11%,respectively.However,neither TGF-?1 neutralizing antibody nor NAC alone could regulate aldosterone-induced PAI-1 mRNA and protein expression to normal level in 24 hours.Conclusions ROS and TGF-?1 play important roles in up-regulation of aldosterone- induced PAI-1 in MCs.ROS and TGF-?1 are not the exclusive pathway of PAI-1 expression induced by aldosterone in MCs.